Chemical Sciences, Pharmaceutical Sciences, Medical Sciences


Novel Anti-osteoporosis Drug Candidate CDRI-99/373


Chemical Sciences, Pharmaceutical Sciences, Medical Sciences

Focus Area:

Post Menopausal Osteoporosis


CA2524568, IN237915, US7582653

Social Benefits:

Compound 99/373 is antiresorptive agent would be useful for osteoporosis that commences after menopause, aging and other estrogen deficiency states, Compound has no/negligible estrogenic profile (Uterotrophic side effect) on genital tract tissue, Compound has low thrombogenic activity in comparison to known drug (Raloxifene)Completed preclinical studies and Permission for conducting phase I Clinical trial has been obtained from DCGI

Developing Agency:

CSIR-Central Drug Research Institute (CDRI), Uttar Pradesh

Technology Readiness Index:

Technology Development

Website Link :
Source (more info) :

Brief Description

Description :

CSIR-CDRI has identified a novel small molecule abbreviated as 99/373 which is aryl napthyl derivative. It specifically inhibits differentiation of bone marrow cells to osteoclasts and disrupts actin ring formation, a surrogate for bone resorption activity by the osteoclasts. This molecule in its category has been found to be more effective than Raloxifene available in the market. This antiresorptive molecule has potential application in reducing the risk of post menopausal osteoporosis.

Related Technologies